Co-Authors
This is a "connection" page, showing publications co-authored by L JEFFREY MEDEIROS and ELIAS JOSEPH JABBOUR.
Connection Strength
1.286
-
Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia. Am J Hematol. 2024 Nov; 99(11):2244-2248.
Score: 0.061
-
Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood Cancer J. 2024 01 25; 14(1):19.
Score: 0.059
-
Recurrent lymphoid and myeloid relapses due to treatment cessations reveal natural history of Ph-positive?B-ALL and pose a diagnostic challenge. Am J Hematol. 2024 04; 99(4):721-726.
Score: 0.059
-
Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group. Mod Pathol. 2024 Feb; 37(2):100406.
Score: 0.058
-
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology. 2023 Jun; 55(4):514-524.
Score: 0.055
-
ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia. Cancer. 2023 03 15; 129(6):878-889.
Score: 0.054
-
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022 07 07; 140(1):58-72.
Score: 0.053
-
Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma. 2022 04; 63(4):885-893.
Score: 0.051
-
Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clin Cancer Res. 2021 11 01; 27(21):5847-5856.
Score: 0.049
-
Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. 2021 10 01; 127(19):3552-3565.
Score: 0.049
-
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52.
Score: 0.048
-
High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia. Eur J Haematol. 2020 Oct; 105(4):449-459.
Score: 0.046
-
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 08; 186(4):538-548.
Score: 0.042
-
Relapsed B-acute lymphoblastic leukemia with aberrant myeloperoxidase expression following CAR T-cell therapy: A diagnostic challenge. Am J Hematol. 2019 09; 94(9):1049-1051.
Score: 0.042
-
CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica. 2019 04; 104(4):749-755.
Score: 0.041
-
Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. Cancer. 2018 10 01; 124(19):3849-3855.
Score: 0.041
-
Correction: Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6. Oncotarget. 2018 09 28; 9(76):34449.
Score: 0.041
-
P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. Am J Hematol. 2018 11; 93(11):1376-1383.
Score: 0.041
-
High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma. Mod Pathol. 2019 01; 32(1):48-58.
Score: 0.040
-
Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. Eur J Haematol. 2018 May; 100(5):444-454.
Score: 0.039
-
Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2018 05 15; 24(10):2304-2311.
Score: 0.039
-
Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome. Am J Hematol. 2017 08; 92(8):E168-E171.
Score: 0.037
-
Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm. Am J Hematol. 2017 Jun; 92(6):520-528.
Score: 0.037
-
Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report. Medicine (Baltimore). 2016 Oct; 95(41):e4934.
Score: 0.035
-
Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplant. 2017 Jan; 52(1):28-33.
Score: 0.035
-
Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents. J Clin Pathol. 2016 Apr 15.
Score: 0.034
-
Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. Leuk Lymphoma. 2016; 57(4):812-9.
Score: 0.034
-
Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2016 07; 30(7):1606-9.
Score: 0.034
-
Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol. 2015 Aug; 95(2):168-76.
Score: 0.032